1月13日,礼来公司和开Scorpion Therapeutics宣布,礼来公司将收购Scorpion的小分子PI3Kα抑制剂项目STX-478。STX-478是一种每日一次的口服突变选择性PI3Kα抑制剂,目前正在乳腺癌症和其他晚期实体瘤的1/2期临床试验中进行评估。(25亿美元!礼来拟收购Scorpion,获得一款变构PI3Kα抑制剂)STX-478可以代表下一代PI3Kα靶向剂,通过选择性...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.